KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Free Cash Flow (2016 - 2025)

Pfizer (PFE) has disclosed Free Cash Flow for 17 consecutive years, with $4.5 billion as the latest value for Q4 2025.

  • Quarterly Free Cash Flow changed N/A to $4.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 billion through Dec 2025, up 353.98% year-over-year, with the annual reading at $9.1 billion for FY2025, 7.73% down from the prior year.
  • Free Cash Flow for Q4 2025 was $4.5 billion at Pfizer, up from $4.0 billion in the prior quarter.
  • The five-year high for Free Cash Flow was $25.0 billion in Q4 2021, with the low at -$2.4 billion in Q2 2024.
  • Average Free Cash Flow over 5 years is $5.1 billion, with a median of $4.0 billion recorded in 2025.
  • The sharpest move saw Free Cash Flow tumbled 128.6% in 2023, then soared 428.77% in 2024.
  • Over 5 years, Free Cash Flow stood at $25.0 billion in 2021, then dropped by 26.07% to $18.5 billion in 2022, then plummeted by 77.26% to $4.2 billion in 2023, then fell by 3.93% to $4.0 billion in 2024, then increased by 11.71% to $4.5 billion in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $4.5 billion, $4.0 billion, and -$1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.